全文获取类型
收费全文 | 1146篇 |
免费 | 96篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 41篇 |
妇产科学 | 12篇 |
基础医学 | 89篇 |
口腔科学 | 65篇 |
临床医学 | 112篇 |
内科学 | 163篇 |
皮肤病学 | 10篇 |
神经病学 | 59篇 |
特种医学 | 192篇 |
外科学 | 216篇 |
综合类 | 96篇 |
预防医学 | 67篇 |
眼科学 | 8篇 |
药学 | 58篇 |
中国医学 | 24篇 |
肿瘤学 | 29篇 |
出版年
2023年 | 3篇 |
2022年 | 6篇 |
2021年 | 6篇 |
2020年 | 7篇 |
2019年 | 8篇 |
2018年 | 19篇 |
2017年 | 22篇 |
2016年 | 14篇 |
2015年 | 16篇 |
2014年 | 30篇 |
2013年 | 55篇 |
2012年 | 50篇 |
2011年 | 46篇 |
2010年 | 45篇 |
2009年 | 40篇 |
2008年 | 44篇 |
2007年 | 59篇 |
2006年 | 29篇 |
2005年 | 29篇 |
2004年 | 26篇 |
2003年 | 23篇 |
2002年 | 15篇 |
2001年 | 31篇 |
2000年 | 21篇 |
1999年 | 31篇 |
1998年 | 61篇 |
1997年 | 51篇 |
1996年 | 44篇 |
1995年 | 32篇 |
1994年 | 32篇 |
1993年 | 27篇 |
1992年 | 22篇 |
1991年 | 23篇 |
1990年 | 16篇 |
1989年 | 39篇 |
1988年 | 31篇 |
1987年 | 32篇 |
1986年 | 25篇 |
1985年 | 31篇 |
1984年 | 17篇 |
1983年 | 13篇 |
1982年 | 15篇 |
1981年 | 10篇 |
1980年 | 11篇 |
1979年 | 4篇 |
1978年 | 6篇 |
1977年 | 6篇 |
1976年 | 10篇 |
1975年 | 6篇 |
1973年 | 3篇 |
排序方式: 共有1247条查询结果,搜索用时 15 毫秒
41.
目的:总结以病人为中心的口腔科门诊数字化建设的经验。方法:从诊疗手段、就医流程、医疗文书以及科室管理4个方面总结广州军区武汉总医院口腔科门诊数字化建设的概况。结果:2009年以来开始进行El腔科门诊的数字化建设,经过3年多的运行,科室工作流程优化明显,提高了工作效率和医疗服务质量。结论:科室的数字化建设有助于提高科室的工作效率和医疗服务质量,充分体现了”以病人为中心”这一理念。 相似文献
42.
Anne Broe Zandra Nymand Ennis Anton Pottegård Jesper Hallas Thomas Ahern Per Damkier 《Basic & clinical pharmacology & toxicology》2017,121(3):153-158
Phthalates are known endocrine disruptors. Not commonly recognized, phthalates are used as excipients in a number of drug formulations. We aimed to describe the sale of phthalate‐containing drugs in Denmark from 2004 to 2015. National data on annual sale of medications (tablets only) were accessed from medstat.dk. Data from the Danish Medicines Agency on phthalate content per tablet were merged with data on total sale for each active substance and drug formulation. We used the ‘defined daily dose’ (DDD) as the unit of sale and calculated the total amount of phthalate (mg) dispensed per 1000 inhabitants. Specific tablet content was compared with the maximum daily exposure limits defined by regulatory agencies for diethyl phthalate (DEP) and dibutyl phthalate (DBP) of 4.0 and 0.01 mg/kg/day, respectively. Use of phthalate‐containing drugs in Denmark was common. We found 154 drug products containing five different phthalates. Two low‐molecular‐weight phthalates and three high‐molecular‐weight phthalates were identified, with a total sale of 59.4 and 112 DDD per 1000 inhabitants per day during the study period, respectively. The highest amount of DBP was found in multi‐enzymes (24.6–32.8 mg per DDD) and mesalazine (12.5–26.4 mg per DDD). Budesonide, lithium and bisacodyl also exceeded the DBP exposure limit of 0.01 mg/kg/day. Other drugs had high levels of DEP, although not exceeding the exposure limit. Sales of phthalate‐containing drugs in Denmark from 2004 to 2015 were substantial, and phthalate exposure from several products exceeded the regulatory exposure limit introduced in 2014. 相似文献
43.
44.
GA Antoniou D Murray SA Antoniou G Kuhan F Serracino-Inglott 《Annals of the Royal College of Surgeons of England》2014,96(3):184-189
Introduction
The retrojugular approach for carotid endarterectomy (CEA) has been reported to have the advantages of shorter operative time and ease of dissection, especially in high carotid lesions. Controversial opinion exists with regard to its safety and benefits over the conventional antejugular approach.Methods
A systematic review of electronic information sources was conducted to identify studies comparing outcomes of CEA performed with the retrojugular and antejugular approach. Synthesis of summary statistics was undertaken and fixed or random effects models were applied to combine outcome data.Findings
A total of 6 studies reporting on a total of 740 CEAs (retrojugular approach: 333 patients; antejugular approach: 407 patients) entered our meta-analysis models. The retrojugular approach was found to be associated with a higher incidence of laryngeal nerve damage (odds ratio [OR]: 3.21, 95% confidence interval [CI]: 1.46–7.07). No significant differences in the incidence of hypoglossal or accessory nerve damage were identified between the retrojugular and antejugular approach groups (OR: 1.09 and 11.51, 95% CI: 0.31–3.80 and 0.59–225.43). Cranial nerve damage persisting during the follow-up period was similar between the groups (OR: 2.96, 95% CI: 0.79–11.13). Perioperative stroke and mortality rates did not differ in patients treated with the retrojugular or antejugular approach (OR: 1.26 and 1.28, 95% CI: 0.31–5.21 and 0.25–6.50).Conclusions
Currently, there is no conclusive evidence to favour one approach over the other. Proof from a well designed randomised trial would help determine the role and benefits of the retrojugular approach in CEA. 相似文献45.
Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R 《Blood》1996,87(5):1710-1717
High-dose cytarabine (ara-c) may overcome cytarabine resistance in leukemic blasts. It has been used as a successful salvage and in postremission therapy but not as initial induction treatment. Patients aged 15 to 60 years, presenting with newly diagnosed acute myeloid leukemia (AML) were randomized to receive either high-dose cytarabine, 3 g/m2 12 hourly on days 1, 3, 5, and 7 for 8 doses, daunorubicin 50 mg/m2 days 1 to 3, etoposide 75 mg/m2 days 1 to 7, (HIDAC-3-7) or standard dose cytarabine 100 mg/m2 continuous intravenous infusion for 7 days with daunorubicin and etoposide at the same dose and schedule as above (7-3-7). Patients could receive a second or third induction course if complete remission (CR) was not achieved. All patients received the same postinduction consolidation therapy (5-2-5) for 2 courses. Eligible patients had no prior chemotherapy or myelodysplastic disease. Patients have been followed for a median of 4.5 years. Of 301 patients treated, complete response (CR) was achieved in 71% with HIDAC- 3-7 and 74% with 7-3-7. For patients in CR, the estimated median remission duration was 45 months with HIDAC-3-7 and 12 months with 7-3- 7 (P = .0005 univariate analysis, P = .0004 multivariate analysis). The estimated percentage of patients relapse free 5 years after achieving a CR was 49% on HIDAC-3-7 and 24% on 7-3-7. Patients in CR tended to survive longer with HIDAC-3-7 but there were no overall survival differences between the two arms. HIDAC-3-7 was associated with significantly more toxicity in induction with more leukopenia, thrombocytopenia, nausea, and vomiting and eye toxicity (all P < .001) but a similar incidence of severe central nervous system and cerebellar toxicity compared to 7-3-7. The consolidation treatment was the same in both arms but caused significantly more leukopenia and thrombocytopenia in patients previously treated with HIDAC-3-7 induction (P < .0001). We conclude that a dose-effect exists for cytarabine in AML and that HIDAC- 3-7 prolongs remission duration and disease-free survival and is tolerable when used as initial induction therapy in patients with de novo AML. 相似文献
46.
GA FitzGerald 《Circulation》1998,98(22):2363-2364
47.
Fibronectin binding to thrombin-stimulated platelets: evidence for fibrin(ogen) independent and dependent pathways 总被引:2,自引:0,他引:2
Plasma fibronectin binds in a specific and saturable manner to thrombin- stimulated platelets. gamma-Thrombin stimulated 80% as much fibronectin binding to platelets as alpha-thrombin with conversion of less than or equal to 1% of platelet fibrinogen to fibrin. Afibrinogenemic and normal platelets bound similar quantities of fibronectin in the presence of calcium or magnesium-ethylene glycol tetra-acetic acid (EGTA). These observations indicate that fibronectin can interact with platelets without involvement of fibrin or fibrinogen. Nevertheless, two different effects of fibrin(ogen) on fibronectin binding were observed. First, exogenous fibrinogen inhibited fibronectin binding to thrombin-stimulated platelets. This inhibition was unidirectional, as fibronectin did not inhibit fibrinogen binding to ADP or thrombin- stimulated cells. Second, formaldehyde-fixed cells with surface- associated fibrin bound significant quantities of fibronectin. This interaction required calcium and did not occur on fixed cells with or without surface-bound fibrinogen. A portion of the ligand bound to fixed cells with surface-associated fibrin was modified to form a derivative with a molecular weight identical to that of the fibronectin subunit cross-linked to the alpha-chain of fibrin. This high mol wt derivative was also observed to a variable extent with living cells in the presence of magnesium or calcium but not in the presence of magnesium-EGTA. Thus, fibronectin binds to platelets by at least two mechanisms: (1) a fibrin(ogen)-independent pathway that requires divalent ions and is inhibited by exogenous fibrinogen; and (2) a fibrin-dependent pathway with an absolute calcium requirement. With nonaggregated, thrombin-stimulated platelets, the former pathway appears to predominate. 相似文献
48.
49.
目的建立大鼠心肌梗死后心力衰竭模型,并进行评估,以提高存活率和成功率。方法分批对70只SD大鼠行冠状动脉左前降支结扎术,同时设15只假手术组,并计算死亡率。于4周时行血流动力学检查,检测心率(HR)、左心室舒张末压(LVEDP)、左室压力最大上升速率(+dp/dtmax)以及左室压力最大下降速率(-dp/dtmax)。结果4周时模型组HR、+dp/dtmax和-dp/dtmax绝对值均低于假手术组(P<0.05),LVEDP则高于假手术组(P<0.05)。随着手术大鼠例数增多,存活率得到提高(P<0.05)。结论心肌梗死后4周形成心力衰竭模型,通过经口气管插管法、选择结扎冠状动脉分支末梢部位、增加手术操作熟练程度,可提高动物存活率。 相似文献
50.
目的 观察兰索拉唑与莫沙必利联合治疗反流性食管炎的临床效果.方法 89例反流性食管炎患者随机分为两组,治疗组50例用兰索拉唑和莫沙必利,对照组39例用盐酸雷尼替丁胶囊,观察治疗前及治疗后4、8周的临床症状改善情况和内镜变化.结果 用药4周时,治疗组反酸、恶心及胸骨后疼痛治疗有效率分别为78%、84%、82%,与对照组比较差异有统计学意义(P<0.05).用药8周结束时,治疗组反酸、恶心及胸骨后疼痛全部改善,总有效率分别是98%、98%和93%,明显优于对照组的64%、81%和73%(均P<0.05);内镜4周、8周复查治疗组与对照组食管黏膜病损愈合率分别为84%和62%,96%和77%,差异有统计学意义(P<0.05).结论 兰索拉唑、莫沙必利联合用药是治疗反流性食管炎安全、有效的方法. 相似文献